New cocktail of four drugs hopes to fight Hard-to-Treat bile duct cancer
NCT ID NCT06893380
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a combination of four drugs—gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab—in people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not been treated before. The goal is to see if this mix can shrink tumors and improve survival. The trial is enrolling 61 adults in South Korea and will also monitor side effects closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab
What this could lead to
If it works, this could offer a more effective treatment option for people with advanced biliary tract cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial with only 61 participants, so results may not apply to everyone. The combination of four drugs may cause significant side effects, and the benefit over standard therapy is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••